Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine effect on CSF volume and brain stiffness
NCT03757897Phase 1Withdrawn
- Sponsor
- Yale University
- Start
- Dec 2021
- Primary completion
- Dec 2022
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of dexmedetomidine in intracranial hypertension (IH), sponsored by Yale University. Primary endpoint: CSF volume increase by 10% at 2.5 hours. Planned start Dec 2021; status: withdrawn.
02
Drugs
dexmedetomidine
03
Conditions
intracranial hypertension (IH)
Beyond the preview
Go deeper on NCT03757897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03757897.